{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["McKelvey BA"],"funding":["Intramural NIH HHS","NCI NIH HHS","National Institutes of Health","NIH HHS","NIGMS NIH HHS","National Science Foundation"],"pagination":["403-409"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9927632"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["60(6)"],"pubmed_abstract":["Alterations in the genome, including mutations and copy number variation (CNV), can drive cancer progression. The Cancer Genome Atlas (TCGA) project studying papillary thyroid cancer (PTC) identified a number of recurrent arm-level copy number amplifications, some spanning genes that are also commonly mutated in thyroid cancer. Herein, we focus on the role of TERT and BRAF CNV in PTC, including its relation to mutation status, gene expression, and clinicopathological characteristics. Utilizing TCGA CNV data, we identified focal amplifications and deletions involving the TERT and BRAF loci. TERT amplifications are more frequent in later stage thyroid tumors; in contrast, BRAF amplifications are not associated with stage. Furthermore, TERT amplifications are more frequently found in tumors a"],"journal":["Genes, chromosomes & cancer"],"pubmed_title":["Characterization of TERT and BRAF copy number variation in papillary thyroid carcinoma: An analysis of the cancer genome atlas study."],"pmcid":["PMC9927632"],"funding_grant_id":["R01 CA222779","T32‐GM007445","R01CA222779","ZIE BC011992","T32 GM007445","1746891","T32-GM007445"],"pubmed_authors":["Zeiger MA","McKelvey BA","Umbricht CB"],"additional_accession":[]},"is_claimable":false,"name":"Characterization of TERT and BRAF copy number variation in papillary thyroid carcinoma: An analysis of the cancer genome atlas study.","description":"Alterations in the genome, including mutations and copy number variation (CNV), can drive cancer progression. The Cancer Genome Atlas (TCGA) project studying papillary thyroid cancer (PTC) identified a number of recurrent arm-level copy number amplifications, some spanning genes that are also commonly mutated in thyroid cancer. Herein, we focus on the role of TERT and BRAF CNV in PTC, including its relation to mutation status, gene expression, and clinicopathological characteristics. Utilizing TCGA CNV data, we identified focal amplifications and deletions involving the TERT and BRAF loci. TERT amplifications are more frequent in later stage thyroid tumors; in contrast, BRAF amplifications are not associated with stage. Furthermore, TERT amplifications are more frequently found in tumors a","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jun","modification":"2025-04-04T00:02:54.763Z","creation":"2025-04-04T00:02:54.763Z"},"accession":"S-EPMC9927632","cross_references":{"pubmed":["33305870"],"doi":["10.1002/gcc.22928"]}}